- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07577388
Bed Rest With a Short Cervix on Preterm Birth (BEWISE)
BEWISE - Bed Rest With a Short Cervix on Preterm Birth
Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.
The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.
The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).
The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.
Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.
Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.
The primary outcome is gestational age in days (continuous).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Kirsten Bünemann, Medical Doctor, PhD-student
- Telefonnummer: +45 40329849
- E-Mail: kirsten.bunemann@clin.au.dk
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Pregnant women with gestational age 20+0 to 33+6
- Cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies
- Above 18 years of age
- Reads and understands Danish or English
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Activity Restriction
The comparison arm reflects current Danish clinical practice in each participating region.
According to national recommendations, AR is indicated before GA 28+0, with the level of restriction determined by cervical length and clinical context.
In singleton pregnancies with a cervix <10 mm in singleton/<15 mm in twins, strict AR is prescribed, defined as bed rest with only toilet allowance.
In addition, thrombosis prophylaxis (Low Molecular Weight Heparin and compression stockings) is initiated in cases of strict AR.
In women with a cervix of 10-14 mm in singletons/15-20 mm in twins, or in cases of PPROM with a cervix <25 mm, moderate AR is prescribed, defined as 2-8 hours of daily bed rest.
The regimen is continued until 28 weeks of gestation.
|
Recommendation to restrict physical activity in pregnant women with a short cervix.
This may include increased rest or bed rest according to local clinical practice.
Andere Namen:
|
|
Experimental: No Activity Restriction
The intervention consists of a recommendation of NAR during pregnancy. No general or graded restrictions on daily activities are advised, and cervical length is not an indication for activity limitation, in line with current evidence. The NAR recommendation is supported by a pragmatic clinical guidance. Women are advised to avoid activities that provoke pain, increase uterine contractions, or worsen pelvic pressure. Decisions regarding hospital admission or sick leave are based on individual clinical assessment rather than cervical length. Specific advice may be provided when clinically indicated. Women are generally advised to avoid heavy weight-bearing exercise and lifting of objects exceeding approximately 10 kg. Otherwise, no specific restrictions on physical activity are imposed, provided that activities do not provoke symptoms such as pain, increased uterine contractions, or pelvic pressure. Sexual activity may be ad-dressed on an individual basis following clinical assessment. |
Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Gestational age at birth
Zeitfenster: At birth (from inclusion until delivery)
|
Gestational age at birth measured in completed days of pregnancy.
This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).
|
At birth (from inclusion until delivery)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Birth before 37 weeks of gestation
Zeitfenster: At birth
|
At birth
|
|
|
Gestational age at birth, pooled
Zeitfenster: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Latency from inclusion to birth (days)
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Onset of birth
Zeitfenster: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Mode of birth
Zeitfenster: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
- Non-occipital presentation
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Interventions during birth
Zeitfenster: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Degree of birth tear
Zeitfenster: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Maternal serious morbidity
Zeitfenster: From inclusion to 42 days after delivery
|
Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications
|
From inclusion to 42 days after delivery
|
|
Umbilical cord arterial pH
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
EPDS depression score
Zeitfenster: From inclusion to 8 weeks after due date
|
From inclusion to 8 weeks after due date
|
|
|
Bone turnover marker level
Zeitfenster: At inclusion and after 4 and 8 weeks.
|
|
At inclusion and after 4 and 8 weeks.
|
|
Lumbar spine Z-score
Zeitfenster: 12 months after stopped breastfeeding
|
12 months after stopped breastfeeding
|
|
|
Data from SENS activity tracker
Zeitfenster: At birth (from inclusion until delivery)
|
Step count Time in supine position
|
At birth (from inclusion until delivery)
|
|
Neonatal mortality
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Fetal loss
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Birth weight
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Neonatal admission, days
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
CNS morbidity
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
|
Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Gastrointestinal morbidity
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
|
Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory support
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
|
Mechanical ventilation or non-invasive ventilation (NIV)
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory distress syndrome (RDS)
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
Early onset infection
Zeitfenster: From inclusion to 5 days after birth
|
Definition: >5 days of i.v.
antibiotics where the treatment starts within the first week after delivery.
|
From inclusion to 5 days after birth
|
|
Apgar score at 5 minutes
Zeitfenster: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Julie Glavind, Senior Consultant, MD, PhD, Aarhus Univeristy Hospital, Department of Obstetrics and Gynecology
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Psychische Störungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Geburtsbedingte Geburtskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Stimmungsschwankungen
- Gebärmutterhalskrankheiten
- Puerperale Störungen
- Depression
- Abtreibung, gewohnheitsmäßig
- Abtreibung, spontan
- Verhalten
- Frühgeburt
- Schwangerschaftskomplikationen
- Depressionen, nach der Geburt
- Geburtshilfe, Frühgeburt
- Zervikale Inkompetenz der Gebärmutter
- Motorik
- Motorik
- Bewegung
- Phänomen des Bewegungsapparates muskuloskelettal
- Muskuloskelettaler und neuronales physiologisches Phänomen
- Therapeutika
- Übung
- Bettruhe
Andere Studien-ID-Nummern
- 16-0500-15
- 4308-00216B (Andere Zuschuss-/Finanzierungsnummer: Independent Research Fund Denmark)
- 1-10-72-96-25 (Andere Kennung: De Videnskabsetiske Komitéer For Region Midtjylland)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Physische Aktivität
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University...RekrutierungAltersspanne ≥16 Jahre, Geschlecht unbegrenzt | Histopathologie bestätigtes diffuses großzelliges B-Zell-Lymphom oder hochgradiges B-Zell-Lymphom | Erhaltene vorherige Erstlinien-Chemotherapie für DLBCL oder HGBL, CR für vier Zyklen nicht erreicht oder rezidiviert | Mindestens eine... und andere BedingungenChina
Klinische Studien zur Activity Restriction
-
George Fox UniversityUnbekanntMuskelschwäche | Kann eine Therapie zur Einschränkung des Blutflusses den Kraftzuwachs in der Rotatorenmanschette steigern?Vereinigte Staaten
-
NRG OncologyPennsylvania Department of Health Commonwealth Universal Research Enhancement...BeendetNicht-kleinzelliger Lungenkrebs Stadium III | Nicht-kleinzelligem Lungenkrebs | Wiederkehrender nicht-kleinzelliger LungenkrebsVereinigte Staaten
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH); National Institute on Aging (NIA)AbgeschlossenArthroseVereinigte Staaten
-
Rigshospitalet, DenmarkFrederiksberg University Hospital; Defactum, Central Denmark RegionAbgeschlossenSchmerzen im unteren RückenDänemark
-
University Hospital, ToulouseAktiv, nicht rekrutierend
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Rochester; University of Massachusetts...AbgeschlossenBrustkrebs | Brustkrebs-Überlebende | Fitness-TrackerVereinigte Staaten
-
Maastricht University Medical CenterSt. Antonius Hospital; Gelderse Vallei Hospital; ild care foundationAbgeschlossenErmüdung | Sarkoidose
-
Emory UniversityNational Institute on Aging (NIA)AbgeschlossenDemenz | Alzheimer ErkrankungVereinigte Staaten
-
Creighton UniversityNational Institutes of Health (NIH)AbgeschlossenLeichte kognitive Einschränkung | Burnout der PflegekraftVereinigte Staaten
-
Cairo UniversityRekrutierungNicht alkoholische FettleberÄgypten